Key Points:
- People stopping weight-loss injections like Wegovy or Mounjaro regain weight four times faster than traditional dieters.
- Study data shows users return to their pre-treatment body weight within an average of 18 months after quitting.
- Experts warn that weight-loss jabs should be seen as a lifelong commitment rather than a temporary solution for obesity.
The medical world is raising a cautionary flag for users of blockbuster weight-loss medications like Wegovy and Mounjaro. New research published in the British Medical Journal suggests that weight returns significantly faster once these injections stop. While patients achieve impressive initial results, the physical “snap back” may occur four times faster than traditional dieting methods.
The comprehensive study analyzed data from over 9,000 patients across 37 different medical trials. Researchers focused on the long-term outcomes of people using GLP-1 agonists compared to those utilizing lifestyle changes. The results provide a stark reality check for anyone viewing these injections as a permanent, one-time fix.
On average, patients using these advanced treatments lose roughly one-fifth of their total body weight. However, the data shows a monthly weight regain of 0.8 kg immediately after the medication ends. At this specific pace, users typically return to their original starting weight within just 18 months of stopping.
Conventional dieting and exercise programs generally produce less dramatic initial weight loss results. Yet, the weight tends to return much more slowly in these cases, averaging about 0.1 kg per month. This suggests that behavioral changes may offer a more stable foundation for maintaining long-term health.
Dr. Susan Jebb of Oxford University emphasizes that patients must understand these risks before starting treatment. She notes that the hunger-suppressing effects of the drugs vanish almost immediately after the final dose. Without the chemical “shield” against appetite, many individuals find it impossible to maintain their new eating habits.
The study also tracked vital health markers such as blood pressure and cholesterol levels during the follow-up period. Unfortunately, these cardiovascular benefits often disappear in parallel with the returning weight. Most heart health improvements reverted to their original pre-treatment levels within approximately 1.4 years.
Health experts now suggest that obesity should be managed as a chronic, lifelong condition rather than a temporary problem. The NHS currently recommends these jabs primarily for those with obesity-related health risks rather than cosmetic weight loss. This ensures that the benefits of the medication outweigh the high risk of a rapid relapse.
To mitigate the rebound effect, doctors are increasingly prescribing intense lifestyle support alongside the medication. Learning new skills in nutrition and physical activity remains essential for anyone hoping to quit the jabs. Some clinicians even suggest that many patients may require a permanent, low-dose maintenance plan.
Further research is still needed to understand the “real-world” implications beyond controlled clinical trials. The current data largely comes from studies lasting only one year after the cessation of treatment. As more millions start these drugs, the long-term impact on global health systems will become much clearer.
